medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 3

<< Back Next >>

Med Int Mex 2021; 37 (3)

Epidemiologic factors associated with mortality among hospitalized adult patients with COVID-19 in the state of Jalisco, Mexico

Andrade-Castellanos CA, Colunga-Lozano LE

Language: Spanish
References: 26
Page: 366-372
PDF size: 205.86 Kb.


ABSTRACT

Background: The SARS-CoV-2 outbreak is a significant challenge to the healthcare system in Mexico; some regions are already struggling to fight the virus.
Objective: To identify comorbidities of adult patients with COVID-19 treated in hospitals in Jalisco and to assess their associations with the risk of death.
Materials and Methods: An observational, analytical, retrospective study in which we obtained data of confirmed COVID-19 cases and their characteristics from epidemiological surveillance system of the Mexican Health Secretary through Feb 27, 2020 to November 30, 2020.
Results: We included 5590 patients with a mean age of 58 years, 62% were men; overall mortality was 38%. The most common concomitant conditions were hypertension, diabetes and obesity. The multivariate analysis found that chronic kidney disease (OR = 2.71), obesity (OR = 1.24), chronic obstructive pulmonary disease (OR = 1.21), diabetes mellitus (OR = 1.15) and hypertension (OR = 1.13) were independent risk factors associated with mortality.
Conclusions: The risk of dying was clearly higher in individuals with comorbidities, particularly among people with chronic kidney disease or obesity.


REFERENCES

  1. World Health Organization. Coronavirus disease (COVID- 2019) situation reports. (Consultado el 30 noviembre de 2020). https://www.who.int/emergencies/diseases/ novel-coronavirus-2019/situation-reports.

  2. Vejar-Aguirre T, Jáuregui-Ulloa E, Gallo-Sánchez K, Mejía- García JA, et al. Evidencias y tendencias para tomar decisiones sobre medidas de contención y mitigación de Covid-19 en Jalisco, México. Salud Publica Mex 2020; 62 (5): 457-459. doi. https://doi.org/10.21149/11724

  3. Ortiz-Brizuela E, Villanueva-Reza M, González-Lara MF, Tamez-Torres KM, et al. Clinical and epidemiological characteristics of patients diagnosed with COVID-19 in a tertiary care center in Mexico city: a prospective cohort study. Rev Invest Clin 2020; 72 (4): 252-258. doi. 10.24875/ RIC.20000334.

  4. Suárez V, Suárez-Quezada M, Oros-Ruiz S, Ronquillo De Jesús E. Epidemiology of COVID-19 in Mexico: from the 27th of February to the 30th of April 2020. Rev Clin Esp 2020; 220 (8): 463-471. doi. 10.1016/j.rce.2020.05.007.

  5. Carrillo-Vega MF, Salinas-Escudero G, García-Peña C, Gutiérrez-Robledo LM, et al. Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico. PLoS One 2020; 15 (9): e0238905. https://doi. org/10.1371/journal.pone.0238905.

  6. Álvarez-López DI, Espinoza-Molina MP, Cruz-Loustaunau ID, Álvarez-Hernández G. La diabetes e hipertensión arterial como factores asociados con la letalidad por Covid-19 en Sonora, México, 2020. Salud Publica Mex 2020; 62 (5): 456-457. https://doi.org/10.21149/11546.

  7. Instituto de Información Estadística y Geográfica del Estado de Jalisco [Internet]. [Consultado el 30 de noviembre de 2020]. Disponible en: https://iieg.gob.mx/ns/wp-content/ uploads/2020/04/ESEP-medicos.pdf y Recursos-en-Salud. pdf.

  8. Gobierno del estado de Jalisco. Plan Jalisco COVID-19 [Internet]. En: Datos abiertos [consultado el 30 de noviembre de 2020]. https://coronavirus.jalisco.gob.mx/ datos-abiertos/

  9. Secretaría de Salud, Gobierno de México. Datos abiertos – Bases Históricas [Internet]. En: Dirección General de Epidemiología. México. 2020 [consultado el 30 de noviembre de 2020]. https://www.gob.mx/salud/documentos/ datos-abiertos-bases-historicas-direccion-general-deepidemiologia.

  10. Wang D, Hu B, Hu C, Zhu F, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China. JAMA 2020; 323 (11): 1061-1069. doi. 10.1001/jama.2020.1585.

  11. Yang J, Zheng Y, Gou X, Pu K, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-95. doi. 10.1016/j.ijid.2020.03.017.

  12. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020; 323 (20): 2052-2059. doi. 10.1001/jama.2020.6775.

  13. Li B, Yang J, Zhao F, Zhi L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109 (5): 531-538. doi. 10.1007/ s00392-020-01626-9.

  14. Grasselli G, Zangrillo A, Zanella A, Antonelli M, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323 (16): 1574-1581. doi.10.1001/ jama.2020.5394.

  15. Casas-Rojo JM, Antón-Santos JM, Millán-Núñez-Cortés J, Lumbreras-Bermejo C, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. Rev Clin Esp (Barc) 2020; 220 (8): 480-494. doi. 10.1016/j.rce.2020.07.003.

  16. Hernández-Galdamez DR, González-Block MÁ, Romo- Dueñas DK, Lima-Morales R, et al. Increased risk of hospitalization and death in patients with covid-19 and pre-existing noncommunicable diseases and modifiable risk factors in Mexico. Arch Med Res 2020; 51 (7): 683-689. doi. 10.1016/j.arcmed.2020.07.003.

  17. Carrillo-Vega MF, Salinas-Escudero G, García-Peña C, Gutiérrez-Robledo LM, et al. Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico. PLoS One 2020; 15 (9): e0238905. https://doi. org/10.1371/journal.pone.0238905.

  18. Kammar-García A, Vidal-Mayo JJ, Vera-Zertuche JM, Lazcano- Hernández M, et al. Impact of comorbidities in Mexican SARS-CoV-2 positive patients: a retrospective analysis in a national cohort. Rev Invest Clin 2020; 72 (3): 151-158.

  19. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición (ENSANUT). México: Instituto Nacional de Salud Pública; 2018.

  20. Garcia-Garcia G, Briseño-Rentería G, Luquín-Arellan VH, Gao Z, et al. Survival among patients with kidney failure in Jalisco, Mexico. J Am Soc Nephrol 2007; 18 (6): 1922-7. doi. 10.1681/ASN.2006121388.

  21. Gutierrez-Padilla JA, Mendoza-Garcia M, Plascencia- Perez S, Renoirte-Lopez K, et al. Screening for CKD and cardiovascular disease risk factors using mobile clinics in Jalisco, Mexico. Am J Kidney Dis 2010; 55 (3): 474-84. doi. 10.1053/j.ajkd.2009.07.023.

  22. Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy. Am J Kidney Dis 2014; 63 (3): 506-20. doi. 10.1053/j.ajkd.2013.10.062.

  23. Sánchez-Álvarez JE, Pérez Fontán M, Jiménez Martín C, Blasco Pelícano M, et al. SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). Nefrologia 2020; 40 (3): 272-278. doi. 10.1016/j. nefro.2020.04.002.

  24. Al-Benna S. Association of high-level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients. Obes Med 2020; 19: 100283. doi. 10.1016/j.obmed.2020.100283

  25. Cortés-Tellés A, López-Romero S, Mancilla-Ceballos R, Ortíz-Farías DL, et al. Risk factors for mortality among hospitalized patients with COVID-19. An overview in Mexican population. Tuberc Respir Dis (Seoul). 2020; 83 (Supple 1): S46-S54. doi. 10.4046/trd.2020.0095.

  26. Mahase E. Covid-19: Deaths in Mexico triple since reopening began in June. BMJ 2020; 370. https://doi. org/10.1136/bmj.m2753.




2020     |     www.medigraphic.com